Antiarrhythmic Drug Now Available in Oral Solution Formulation

Antiarrhythmic Drug Now Available in Oral Solution Formulation
Antiarrhythmic Drug Now Available in Oral Solution Formulation

Arbor announced the launch of Sotylize (sotalol HCl) oral solution for the treatment of life-threatening ventricular arrhythmias and for the maintenance of normal sinus rhythm in patients with highly symptomatic atrial fibrillation/atrial flutter. Sotylize is the first oral solution formulation of sotalol.

Sotalol, an antiarrhythmic, has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. Sotalol HCl consists of a racemic mixture of two isomers, both of which have similar Class III antiarrhythmic effects.

RELATED: Antiarrhythmic Agent Sotylize Gets FDA Approval

Sotylize oral solution is grape flavored and is available as a 5mg/mL strength in 250mL and 480mL bottles.

For more information call (866) 516-4950 or visit Sotylize.com.

Loading links....